戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d for alendronate, calcitonin, glipizide, or quinapril.
2 giotensin-converting enzyme (ACE) inhibitor, quinapril.
3 gebrium (1 mg/kg/day), or the ACE inhibitor, quinapril (30 mg/kg/day), for 20 weeks, and renal parame
4 e-blind, placebo-controlled study evaluating quinapril 80 mg/day, or the maximum tolerated dosage, in
5  tolerability of prolonged administration of quinapril, a long-acting angiotensin-converting enzyme i
6 07) for pairwise comparison (i.e., ACEIs vs. quinapril, ACEIs vs. trandolapril, ARBs vs. quinapril, o
7                                Specifically, quinapril and trandolapril were found to have a statisti
8  members of the ACEI antihypertensive class (quinapril and trandolapril) have a significantly higher
9 owed significant differences associated with quinapril and trandolapril, compared to other ACEIs and
10            Health status was not affected by quinapril, and one-half of the patients who believed the
11                      Those assigned to 40 mg quinapril continued that dose and those assigned to plac
12                                              Quinapril did not affect the occurrence of digital ulcer
13                            Administration of quinapril for up to 3 years had no demonstrable effects
14 f lcSSc as part of the baseline visit of the Quinapril in Scleroderma trial.
15                                              Quinapril inhibited PepT2-mediated currents in presence
16 mly assigned to one of two groups: 40 mg/day quinapril (n = 177) or placebo (n = 159) for 8 weeks.
17  (for amlodipine, amlodipine-benazepril, and quinapril), non-vertebral fracture (for alendronate and
18 th exacerbation of HAE-FXII during intake of quinapril or enalapril had no further HAE-FXII attacks a
19  quinapril, ACEIs vs. trandolapril, ARBs vs. quinapril, or ARBs vs. trandolapril).
20 -converting enzyme inhibition (ACE-I) (i.e., quinapril) prevents transient ischemia (exertional and s
21           Oocytes expressing PepT2 exhibited quinapril-sensitive outward currents.
22      In the absence of external substrate, a quinapril-sensitive proton inward current (proton leak)
23 CM hamsters, high-dose ACE inhibition alone (quinapril), started at 8 months and continued for 11 wee
24 r group comparison (i.e., ACEIs vs. ARBs vs. quinapril vs. trandolapril) and (P 0.0007) for pairwise
25                                              Quinapril was not tolerated by one-fifth of the patients